title: Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis.
abstract: OBJECTIVE
  Bisphosphonates are the first line treatment options in the prevention and treatment of osteoporosis among elderly women or men. Age associated cognitive decline may increase due to adverse effects of medications. The aim of the present study was to observe the course of cognitive skills in elderly subjects treated with a bisphosphonate.
  
  
  METHODS
  This prospective study enrolled 120 community-dwelling, non-demented women and men with osteoporosis aged 65 and older who were treated with first-ever zoledronic acid. Mini mental state examination (MMSE) was measured along with geriatric depression scale (GDS) measurement, clock drawing test (CDT), and other clinical and laboratory evaluations that could affect cognition at baseline and 12 months. The primary outcome was at least one point decrease in the final MMSE score at one year.
  
  
  RESULTS
  Scores of MMSE (28.29±2.17 and 28.23±2.37, p=0.681), GDS (3.24±2.88 and 2.96±2.88, p=0.062) and CDT (3.69±0.68 and 3.75±0.60, p=0.268) did not change after zoledronic acid infusion at one year. Education in years and presence of newly started medicines with anticholinergic properties was independently associated with at least one point reduction in MMSE score [odds ratio: 3.07 (%95 confidence interval: 1.00-9.44)].
  
  
  CONCLUSIONS
  Among elderly woman and men with osteoporosis, cognitive functions remained stable 12 months after the administration of first-ever zoledronic acid.
authors.affiliation: Geriatric Internist, Gulhane School of Medicine, Department of Internal Medicine, Etlik 06018 Ankara, Turkey. ilkertasci@yahoo.com.
authors.forename: Ilker
authors.initials: I
authors.lastname: Tasci
authors.forename: Umut
authors.initials: U
authors.lastname: Safer
authors.forename: Umit
authors.initials: U
authors.lastname: Cintosun
authors.forename: Ergun
authors.initials: E
authors.lastname: Bozoglu
authors.forename: Ilkin
authors.initials: I
authors.lastname: Naharci
authors.forename: Aydogan
authors.initials: A
authors.lastname: Aydogdu
authors.forename: Coskun
authors.initials: C
authors.lastname: Meric
authors.forename: Huseyin
authors.initials: H
authors.lastname: Doruk
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D060825:Cognitive Dysfunction / Q000139:chemically induced* / Q000175:diagnosis*; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D010024:Osteoporosis / Q000175:diagnosis* / Q000188:drug therapy*; D011446:Prospective Studies; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid